Extracting information from free-text electronic patient records to identify practice-based evidence of the performance of coronary stents
暂无分享,去创建一个
Sukhoon Lee | Dukyong Yoon | Rae Woong Park | Hong-Seok Lim | JungHyun Byun | Hojun Park | D. Yoon | Yoon Seob Kim | Junghyun Byun | Hojun Park | Ahram Lee | I. Kim | Sukhoon Lee | H. Lim | Ahram Lee | Il Hyun Kim | R. W. Park | Yoon Seob Kim | A. Lee | Il Hyun Kim
[1] Michael S. Lee,et al. Drug‐eluting stent fracture: Incidence, contributing factors, and clinical implications , 2010, Catheterization and cardiovascular interventions : official journal of the Society for Cardiac Angiography & Interventions.
[2] S. Allaqaband,et al. Stent fracture, an incidental finding or a significant marker of clinical in‐stent restenosis? , 2008, Catheterization and cardiovascular interventions : official journal of the Society for Cardiac Angiography & Interventions.
[3] Mark D. Huffman,et al. AHA Statistical Update Heart Disease and Stroke Statistics — 2012 Update A Report From the American Heart Association WRITING GROUP MEMBERS , 2010 .
[4] R. Weiss,et al. Meta-analysis of incidence, clinical characteristics and implications of stent fracture. , 2010, The American journal of cardiology.
[5] B. Gersh,et al. ESC guidelines on the management of stable coronary artery disease — addenda The Task Force on the management of stable coronary artery disease of the European Society of Cardiology , 2013 .
[6] S. Bangalore,et al. Paclitaxel-Eluting versus Everolimus-Eluting Coronary Stents in Diabetes. , 2015, The New England journal of medicine.
[7] Maarten J. IJzerman,et al. Clinical Events and Patient-Reported Chest Pain in All-Comers Treated With Resolute Integrity and Promus Element Stents: 2-Year Follow-Up of the DUTCH PEERS (DUrable Polymer-Based STent CHallenge of Promus ElemEnt Versus ReSolute Integrity) Randomized Trial (TWENTE II). , 2015, JACC. Cardiovascular interventions.
[8] Aloke V. Finn,et al. Delayed Arterial Healing and Increased Late Stent Thrombosis at Culprit Sites After Drug-Eluting Stent Placement for Acute Myocardial Infarction Patients: An Autopsy Study , 2008, Circulation.
[9] H. Wickham. Simple, Consistent Wrappers for Common String Operations , 2015 .
[10] A. Colombo,et al. Biodegradable stents : "fulfilling the mission and stepping away". , 2000, Circulation.
[11] F Unger,et al. Comparison of coronary-artery bypass surgery and stenting for the treatment of multivessel disease. , 2001, The New England journal of medicine.
[12] F Joffre,et al. Intravascular stents to prevent occlusion and restenosis after transluminal angioplasty. , 1987, The New England journal of medicine.
[13] C. Cernigliaro. [Comparison of coronary-artery bypass surgery and stenting for the treatment of multivessel disease]. , 2001, Italian heart journal. Supplement : official journal of the Italian Federation of Cardiology.
[14] M. Togni,et al. Long-term clinical outcomes of biodegradable polymer biolimus-eluting stents versus durable polymer everolimus-eluting stents in patients with coronary artery disease: three-year follow-up of the COMPARE II (Abluminal biodegradable polymer biolimus-eluting stent versus durable polymer everolimus-elu , 2015, EuroIntervention : journal of EuroPCR in collaboration with the Working Group on Interventional Cardiology of the European Society of Cardiology.
[15] P. Smits,et al. Second-generation everolimus-eluting and paclitaxel-eluting stents in real-life practice (COMPARE): a randomised trial , 2010, The Lancet.
[16] F. Eberli,et al. Improved Safety and Reduction in Stent Thrombosis Associated With Biodegradable Polymer-Based Biolimus-Eluting Stents Versus Durable Polymer-Based Sirolimus-Eluting Stents in Patients With Coronary Artery Disease Final 5-Year Report (Limus Eluted From A Durable Versus ERodable Stent Coating) Randomi , 2022 .
[17] E. Bramucci,et al. Sirolimus-eluting versus uncoated stents in acute myocardial infarction. , 2006, The New England journal of medicine.
[18] T. Muramatsu,et al. Incidence and Characteristics of Late Catch-Up Phenomenon Between Sirolimus-Eluting Stent and Everolimus-Eluting Stent: A Propensity Matched Study. , 2015, Journal of interventional cardiology.
[19] F. Eberli,et al. Long-term efficacy and safety of biodegradable-polymer biolimus-eluting stents: main results of the Basel Stent Kosten-Effektivitäts Trial-PROspective Validation Examination II (BASKET-PROVE II), a randomized, controlled noninferiority 2-year outcome trial. , 2015, Circulation.
[20] Suzette J. Bielinski,et al. Use of diverse electronic medical record systems to identify genetic risk for type 2 diabetes within a genome-wide association study , 2012, J. Am. Medical Informatics Assoc..
[21] J Starren,et al. Architectural requirements for a multipurpose natural language processor in the clinical environment. , 1995, Proceedings. Symposium on Computer Applications in Medical Care.
[22] Patrick W Serruys,et al. An everolimus‐eluting stent versus a paclitaxel‐eluting stent in small vessel coronary artery disease: A pooled analysis from the SPIRIT II and SPIRIT III trials , 2010, Catheterization and cardiovascular interventions : official journal of the Society for Cardiac Angiography & Interventions.
[23] S. Pocock,et al. Safety and efficacy of sirolimus- and paclitaxel-eluting coronary stents. , 2007, The New England journal of medicine.
[24] Jeroen J. Bax,et al. 2013 ESC guidelines on the management of stable coronary artery disease: the Task Force on the management of stable coronary artery disease of the European Society of Cardiology. , 2013, European heart journal.
[25] Gaganpreet Kaur,et al. USAGE OF REGULAR EXPRESSIONS IN NLP , 2014 .
[26] E. Braunwald,et al. A tale of coronary artery disease and myocardial infarction. , 2012, The New England journal of medicine.
[27] G. Sarno,et al. Initial clinical experience with an everolimus eluting platinum chromium stent (Promus Element) in unselected patients from the Swedish Coronary Angiography and Angioplasty Registry (SCAAR). , 2013, International journal of cardiology.
[28] G. Dehmer,et al. Drug-eluting coronary artery stents. , 2009, American family physician.
[29] F. Eberli,et al. Long-term clinical outcomes of biodegradable polymer biolimus-eluting stents versus durable polymer sirolimus-eluting stents in patients with coronary artery disease (LEADERS): 4 year follow-up of a randomised non-inferiority trial , 2011, The Lancet.
[30] P. Serruys,et al. Biodegradable polymer drug-eluting stents reduce the risk of stent thrombosis at 4 years in patients undergoing percutaneous coronary intervention: a pooled analysis of individual patient data from the ISAR-TEST 3, ISAR-TEST 4, and LEADERS randomized trials. , 2012, European heart journal.
[31] E. Omerovic,et al. Lower risk of stent thrombosis and restenosis with unrestricted use of 'new-generation' drug-eluting stents: a report from the nationwide Swedish Coronary Angiography and Angioplasty Registry (SCAAR). , 2012, European heart journal.
[32] Gregg W Stone,et al. Everolimus-eluting versus paclitaxel-eluting stents in coronary artery disease. , 2010, The New England journal of medicine.
[33] J.,et al. The New England Journal of Medicine , 2012 .